{"title":"视神经脊髓炎谱系障碍引起的肿瘤性脱髓鞘病变：埃库珠单抗成功预防复发","authors":"Kimberly A. O'Neill , Ukuemi Edema , Lauren Gluck","doi":"10.1016/j.nerep.2023.100188","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Tumefactive demyelinating lesions are rare in multiple sclerosis (MS), and even less frequently seen in NMOSD (neuromyelitis optica spectrum disorder).</p></div><div><h3>Case report</h3><p>A 50-year-old man with large parieto-occipital lesion originally concerning for neoplasm underwent stereotactic brain biopsy. With pathology results and later, positive aquaporin-4 antibody (AQP4), he was subsequently diagnosed with tumefactive demyelinating lesion (TDL) due to AQP4. He was successfully treated with eculizumab.</p></div><div><h3>Discussion</h3><p>Here we demonstrate that eculizumab, a newer agent approved for NMOSD in 2019, can be used successfully for treatment of TDL in NMOSD. As the treatment landscape advances in demyelinating disorders, there should be awareness of the successful use of newer agents in rare clinical presentations.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100188"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumefactive demyelinating lesion due to neuromyelitis optica spectrum disorder: Successful relapse prevention with eculizumab\",\"authors\":\"Kimberly A. O'Neill , Ukuemi Edema , Lauren Gluck\",\"doi\":\"10.1016/j.nerep.2023.100188\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Tumefactive demyelinating lesions are rare in multiple sclerosis (MS), and even less frequently seen in NMOSD (neuromyelitis optica spectrum disorder).</p></div><div><h3>Case report</h3><p>A 50-year-old man with large parieto-occipital lesion originally concerning for neoplasm underwent stereotactic brain biopsy. With pathology results and later, positive aquaporin-4 antibody (AQP4), he was subsequently diagnosed with tumefactive demyelinating lesion (TDL) due to AQP4. He was successfully treated with eculizumab.</p></div><div><h3>Discussion</h3><p>Here we demonstrate that eculizumab, a newer agent approved for NMOSD in 2019, can be used successfully for treatment of TDL in NMOSD. As the treatment landscape advances in demyelinating disorders, there should be awareness of the successful use of newer agents in rare clinical presentations.</p></div>\",\"PeriodicalId\":100950,\"journal\":{\"name\":\"Neuroimmunology Reports\",\"volume\":\"4 \",\"pages\":\"Article 100188\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimmunology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667257X23000268\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X23000268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tumefactive demyelinating lesion due to neuromyelitis optica spectrum disorder: Successful relapse prevention with eculizumab
Background
Tumefactive demyelinating lesions are rare in multiple sclerosis (MS), and even less frequently seen in NMOSD (neuromyelitis optica spectrum disorder).
Case report
A 50-year-old man with large parieto-occipital lesion originally concerning for neoplasm underwent stereotactic brain biopsy. With pathology results and later, positive aquaporin-4 antibody (AQP4), he was subsequently diagnosed with tumefactive demyelinating lesion (TDL) due to AQP4. He was successfully treated with eculizumab.
Discussion
Here we demonstrate that eculizumab, a newer agent approved for NMOSD in 2019, can be used successfully for treatment of TDL in NMOSD. As the treatment landscape advances in demyelinating disorders, there should be awareness of the successful use of newer agents in rare clinical presentations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
